On June 14, 2019 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) reported that it has launched a new generic formulation of oxycodone hydrochloride hydrate injection for cancer pain treatment, Oxycodone Injections 10 mg and 50 mg "Daiichi Sankyo" (hereafter, new formulation), in Japan (Press release, Daiichi Sankyo, JUN 14, 2019, View Source [SID1234537073]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new formulation is the first generic injection containing oxycodone hydrochloride, a strong opioid analgesic providing relief of moderate to severe pain in various types of cancer.

It is manufactured from drug substance to formulation solely by Daiichi Sankyo’s subsidiary in Japan, Daiichi Sankyo Propharma Co., Ltd. (marketing authorization holder).

The addition of the new formulation to our product lineup of opioid analgesics will provide another treatment option for patients suffering from cancer pain and further enhance our contribution to healthcare in Japan.

Product Summary

Product Name

Therapeutic Category

Original Brand Name

Oxycodone Injections 10 mg "Daiichi Sankyo"

Oxycodone Injections 50 mg "Daiichi Sankyo"

Cancer pain treatment

OxiFast Injection 10 mg

OxiFast Injection 50 mg